Chapter 11
Community-Acquired Pneumonia—Back to Basics

Marc J. M. Bonten and Jan Jelrik Oosterheert

Background

Lower respiratory tract infections are among the most common infectious diseases worldwide and are caused by the inflammation and consolidation of lung tissue due to an infectious agent. The clinical criteria for the diagnosis include chest pain, cough, auscultatory findings such as rales or evidence of pulmonary consolidation, fever, or leukocytosis. Radiographic evidence, such as the presence of new infiltrates on chest radiograph, and laboratory evidence can support the diagnosis. Elderly and patients with underlying conditions, such as cerebro- and cardiovascular diseases, chronic obstructive pulmonary disease (COPD), and alcoholism, are at increased risk for developing lower respiratory tract infections and complicated courses of infection. Complications include the development of progressive pneumonia, pleural empyema, uncontrolled sepsis, and death, sometimes even despite appropriate antimicrobial treatment.

Because of differences in pathogenesis and causative microorganisms, healthcare-associated and community-acquired pneumonia (CAP) are usually distinguished. CAP represents a broad spectrum of disease severity, ranging from mild pneumonia that can be managed by general practitioners to severe pneumonia with septic shock needing treatment in the intensive care unit (ICU). Most cases of CAP are successfully managed in primary care and approximately 20 and 1% of patients need hospitalization or treatment in ICU, respectively.

Despite the widespread availability of antibiotics and reduced mortality since their introduction, lower respiratory tract infections remain the most important infectious cause of death in the developed world. For instance, absolute mortality due to pneumonia has increased in the past 10 years in the Netherlands and the United States.

Estimated annual costs for treating CAP were in excess of 1 billion US$ in the United Kingdom in 1997 and 9.7 billion US$ in the United States in 2001.

Lower respiratory tract infections are most frequently caused by bacteria or viruses. Treatment should be directed toward the causative organisms, with antibiotics prescribed only for bacterial infections and being withheld for
nonbacterial causes of inflammation. Yet, causative agents have usually not been identified at the time that treatment must be initiated and empirical therapy should, therefore, cover the most likely pathogens. This implies that it is unavoidable that empirical therapy frequently includes a wider range of pathogens and, thus, a broader antibiotic spectrum than a choice that exclusively covers the pathogen involved.

On a population level, the quantity of antibiotics prescribed is linearly related to antibiotic resistance and unnecessary antibiotic use should, therefore, be prevented. Despite this paradigm, overuse of antibiotics frequently occurs, especially in case of viral infections. Yet, this goal to minimize unnecessary antibiotic use must be balanced constantly against the urge to cover all potential pathogens in order to prescribe optimal treatment for the individual patient. Therefore, optimizing therapeutic efficacy of empirical treatment, while preventing unnecessary antibiotic use have become important issues in the management of lower respiratory tract infections. In this chapter, etiologic, diagnostic, therapeutic, and preventive considerations are described to optimize antibiotic prescription for the individual patient with lower respiratory tract infections, while keeping antibiotic resistance development on a population level in mind.

Etiology

Worldwide, *Streptococcus pneumoniae* is by far the most important pathogen for CAP. Other frequently isolated bacteria are *Haemophilus influenzae* and *Staphylococcus aureus*. Incidences of atypical pathogens, such as *Mycoplasma pneumoniae*, *Chlamydia pneumoniae*, and *Legionella pneumophila*, are generally lower than those of the afore-mentioned bacteria, although variations may be large. *Pseudomonas aeruginosa* can be relevant in patients with structural lung damage, such as those with bronchiectasis or COPD. Most frequent viral causes of CAP include influenza virus and parainfluenza virus. Viral pneumonias due to infection with influenza, respiratory syncytial virus, coronaviruses, parainfluenza virus, and even rhinoviruses can be life threatening in elderly and immunocompromised patients. Influenza pneumonia may be complicated by secondary bacterial infections caused by *S. aureus*, *S. pneumoniae*, *H. influenzae*, or other Gram- negative pathogens.

Recently, coronaviruses have been recognized as causes of severe lower respiratory tract infections. The SARS coronavirus caused severe CAP associated with high mortality rates, even in previously healthy adults. Non-SARS coronaviruses such as the coronavirus OC43 have been associated with lower respiratory tract infections in children and adults. Human metapneumovirus is increasingly recognized as a cause of respiratory failure in children and of pneumonia in the elderly. Importantly, up to 60% of episodes of CAP remain of unknown etiology.
Identification of Causative Pathogens

Rapid and reliable diagnostic results are needed for a prudent and pathogen-tailored antibiotic strategy. Currently available methods for etiological diagnosis include clinical, radiological, and laboratory findings, Gram staining of sputum, urinary antigen tests, or specific DNA detection using real-time polymerase chain reactions (PCR).

Clinical, Radiological, and Laboratory Features

Although some clinical features have been associated with specific causative microorganisms—such as high fever, acute onset of disease, chills, productive cough, and thoracic pain with *S. pneumoniae*, and preceding influenza with *S. aureus*—there is consensus that in most cases, the microbial cause of CAP cannot be predicted using clinical or radiographic features. New opportunities include the use of systemic levels of C-reactive protein (CRP) and procalcitonin (PCT). Yet, although raised CRP and PCT levels have been claimed to be indicative for bacterial infections, CRP levels could not differentiate between bacterial and viral respiratory tract infections in adults, nor could PCT in children admitted with CAP. From another perspective, though, PCT was used to reduce unnecessary antibiotic prescriptions in patients with clinical symptoms of LRTI, without subsequent adverse effect on patient outcomes. Of note, reduction of antibiotic use was primarily achieved through withholding of antimicrobial therapy for patients with acute bronchitis and only 36% of patients had CAP in this study.

Microbiology and Serology

Routine diagnostic procedures to identify causative microorganisms include microbiological culturing of blood and sputum and serological testing of acute and convalescent blood samples. However, the clinical value of these conventional diagnostic methods in guiding treatment of CAP is limited because of low sensitivity and considerable delay. Culturing other samples for which more invasive procedures are needed, such as pleural and bronchoalveolar fluids, might increase diagnostic yields, but inherently suffer from the same diagnostic delay. In one study, fiberoptic bronchoscopy provided an etiological diagnosis in 25% of patients in whom conventional diagnostic methods failed to identify a causative microorganism. Yet, pathogen-directed empirical therapy in this study was not associated with better clinical outcome of patients. Fiberoptic bronchoscopy should, therefore, be considered for cases of treatment failure without identified causative microorganism from conventional diagnostics. Importantly, even in study settings with extensive diagnostic testing, approximately 50% of episodes of CAP remain of unknown etiology.

The use of sputum Gram staining in the diagnostic workup of CAP is controversial: its use is recommended by the Infectious Diseases Society of America
Advantages of sputum Gram staining include its wide availability and low costs. However, adequate sputum samples cannot always be obtained, either because there is no sputum production or because samples are not adequate for evaluation. Furthermore, sensitivity and specificity are unknown, some bacteria cannot be identified, and a uniform definition of a positive stain does not exist.\textsuperscript{45, 46}

### Urinary Antigen Testing

Two urinary antigen tests are available for diagnosing the microbial cause of CAP. The NOW \textit{S. pneumoniae} urinary antigen test (Binax, Inc., Portland, Maine) detects, within 15 minutes, the C polysaccharide wall antigen common to all \textit{S. pneumoniae} strains.\textsuperscript{52} One study reported 90–100\% specificity and 74\% sensitivity.\textsuperscript{53} Yet, specificity might be reduced due to nasopharyngeal carriage of pneumococci.\textsuperscript{54}

The other urinary antigen test detects \textit{L. pneumophila} type I and test accuracy increases with severity of disease, with sensitivities varying from approximately 40\% in mild to 95\% in severe CAP.\textsuperscript{55} Immediate (within 24 hours after hospital admission) therapy for Legionnaires’ disease, as detected by this test, increased ICU-free survival as compared to therapy initiated after > 24 hours.\textsuperscript{56}

### DNA Detection

Another approach is to identify viruses and “atypical” bacterial pathogens in respiratory samples through molecular techniques, such as polymerase chain reaction (PCR). Novel real-time Taq-Man PCR techniques are sensitive and specific and able to detect respiratory viruses in clinical specimens within hours.\textsuperscript{25, 57} Yet, in a randomized trial, addition of real-time PCR analysis of respiratory viruses and atypical pathogens in nose and throat swabs to routine diagnostic workup, improved diagnostic yields but failed to reduce antibiotic use or healthcare-associated costs among patients admitted with lower respiratory tract infections (of whom 50\% had CAP).\textsuperscript{58}

### Therapy

**Microorganisms and Antibiotic Resistance**

A detailed description of the underlying mechanisms of antibiotic resistance is beyond the scope of this chapter. In brief, alterations in the bacterial proteins that bind penicillin can decrease binding affinity and antimicrobial susceptibility to penicillins in \textit{S. pneumoniae}. Such strains are also more likely to be resistant to other antibiotics, such as macrolides, tetracyclins, and fluoroquinolones. For the treatment of pneumococcal pneumonia, \beta-lactam antibiotic concentrations should exceed the MIC for at least 40\% of the time.\textsuperscript{59} When strains with reduced
susceptibility to penicillin are anticipated, this can be achieved with higher dosages of penicillin (e.g., 2 million units q 6 hours) or amoxicillin (e.g., 1 gram q 6 hours). In clinical studies, mortality rates of patients with bacteremic pneumococcal pneumonia and treated with β-lactam antibiotics were comparable for episodes caused by pneumococci susceptible and nonsusceptible to penicillin.  

Macrolide resistance is either due to modification of the target site, encoded by the \textit{ermB} gene, or an active efflux pump that removes macrolides from the cell, encoded by the \textit{mef} gene. In \textit{S. pneumoniae}, the \textit{erm} gene is associated with high levels of resistance to all macrolides. Erythromycin resistance based on efflux mechanisms can be overcome by the use of newer macrolides, such as azithromycin.  

The newer fluoroquinolones, such as levofloxacin and moxifloxacin, are active, \textit{in vitro}, against most relevant significant aerobic Gram-positive cocci, the Enterobacteriaceae, \textit{H. influenzae}, \textit{M. catarrhalis}, Legionella species, \textit{M. pneumoniae}, and \textit{C. pneumoniae}, which make them attractive compounds for treatment of CAP. Development of resistance to fluoroquinolones, which can occur even during treatment, however, is a matter of serious concern. Resistance to fluoroquinolones results from mutations in the target enzymes (DNA gyrase and topoisomerase IV), thereby reducing the inhibitory effects of fluoroquinolones on bacterial DNA synthesis. Strains usually become fully resistant when both target genes are mutated. Other resistance mechanisms include alterations in the bacterial cell membrane and active efflux of the drug.  

Importantly, prevalence of antibiotic resistance varies geographically. For instance, prevalence of reduced susceptibility to penicillin among \textit{S. pneumoniae} is around 40% in Spain and < 1% in the Netherlands (http://www.earss.rivm.nl). Furthermore, over 50% of macrolide resistance in Europe is caused by mutations in the \textit{ermB} gene, whereas presence of an efflux pump is the predominant resistance mechanism of \textit{S. pneumoniae} to macrolides in the United States. Therefore, decisions on empirical antimicrobial treatment should be based on local antibiotic resistance rates.

Recently, an emergence of infections, mostly skin infection but sporadically severe CAP, caused by so-called community-associated methicillin-resistant \textit{S. aureus} (CA-MRSA), have been reported from the United States and Europe. CA-MRSA are resistant to all β-lactam antibiotics, but are frequently still susceptible to clindamycin, co-trimoxazole, and fluoroquinolones.

**Recommended Treatment**

When organisms are known, recommended treatment should be aimed at the isolated pathogen (Table 11.1). However, the initial treatment of CAP, as recommended in recent guidelines, is predominantly based on the clinical severity of presentation rather than the presumed causative pathogen (Table 11.2). For the prediction of clinical severity, several risk classifications exist which include combinations of underlying illnesses, age, and clinical features. In clinical practice, broad-spectrum antibiotics should be prescribed more liberally in patients
| Microorganism               | Preferred targeted therapy                                                                 | Alternative antimicrobial therapy                                      |
|-----------------------------|---------------------------------------------------------------------------------------------|-------------------------------------------------------------------------|
| *S. pneumoniae*             | *Penicillin G*                                                                               | *Cephalosporin*                                                         |
| Penicillin susceptible,     | *Amoxicillin*                                                                                | *Macrolide*                                                            |
| (MIC < 2 μg/ml)             | *Clindamycin*                                                                               | *Fluoroquinolone*                                                      |
| Penicillin resistant        | *Cefotaxime*                                                                                 | *Doxycycline*                                                          |
| *H. influenzae*             | *β-Lactam + β-lactamase inhibitor*                                                           | *Carbapenem*                                                          |
| *M. pneumoniae*             | *Doxycycline*                                                                                | *Fluoroquinolone*                                                      |
| *C. pneumoniae*             | *Doxycycline*                                                                                | *Trimethoprim/sulfamethoxazole*                                        |
| *L. pneumophila*            | *Macrolide ± rifampicin*                                                                     | *Doxycycline ± rifampicin*                                             |
| *S. aureus*                 | *Flucloxacillin ± rifampin*                                                                  | *Cefazolin or cefuroxime*                                              |
| Methicillin susceptible     | *Vancomycin ± rifampicin orgentamicin                                                        | *Vancomycin*                                                          |
| Methicillin resistant       | *Vancomycin ± rifampicin orgentamicin                                                        | *Teicoplanin ± rifampicin*                                             |
| *M. catarrhalis*            | *Cephalosporin (2nd or 3rd generation)*                                                      | *Trimethoprim/sulfamethoxazole*                                        |
| Anaerobes                   | *β-Lactam + β-lactamase inhibitor*                                                           | *Linezolid*                                                           |
| *P. aeruginosa*             | *Aminoglycoside + antipseudomonal β-lactam (e.g., piperacillin)*                             | *Aminoglycoside + ciprofloxacin*                                       |
| Enteric Gram-negative       | *Carbapenem*                                                                                 | *Ciprofloxacin + antipseudomonal β-lactam*                             |
| bacilli                     | *3rd or 4th generation cephalosporin ± aminoglycoside*                                       | *β-Lactam + β-lactamase inhibitor*                                     |
| *C. psittacci*              | *Carbapenem*                                                                                 | *Fluroquinolone*                                                      |
| *Coxiella burnetii*         | *Doxycycline*                                                                                | *Erythromycin*                                                        |
|                             | *Tetracycline*                                                                               | *Chloramphenicol*                                                      |
Table 11.2. Preferred empirical therapy for community-acquired therapy (CAP) in lower respiratory tract infections, based on the recommendations for community-acquired pneumonia of the American Thoracic Society (ATS), British Thoracic Society (BTS), Infectious Diseases Society of America (IDSA), and the Dutch Working Party on Antibiotic Policy (SWAB)

| Severity of CAP          | Recommended treatment in the USA (ATS and IDSA guidelines) | Recommended treatment in the UK (BTS guidelines) | Recommended treatment in the Netherlands (SWAB guidelines) |
|--------------------------|-------------------------------------------------------------|--------------------------------------------------|------------------------------------------------------------|
| Mild infection (outpatients) | • Macrolide or doxycycline                                  | • Amoxicillin                                    | • Amoxicillin                                               |
|                          | • Fluoroquinolone                                           |                                                  | doxycycline                                                |
| Moderately severe infection (inpatients) | • Extended-spectrum cephalosporin plus macrolide            | • Amoxicillin + macrolide                        | • Amoxicillin                                               |
|                          | • β-Lactam/β-lactamase inhibitor plus macrolide             | if mild infection, but admitted for other reasons than pneumonia, e.g., social situation or other condition | • Amoxicillin                                               |
|                          | • Fluoroquinolone                                           |                                                  | Penicillin                                                 |
| Severe infection (ICU treatment) | • Extended-spectrum cephalosporin plus macrolide            | • β-Lactam + β-lactamase inhibitor plus macrolide | • Moxifloxacin                                              |
|                          | • β-Lactam/β-lactamase inhibitor plus either fluoroquinolone or macrolide | • Cephalosporin (2nd/3rd generation) plus macrolide | • Penicillin + iprofloxacin                               |
| Structural lung disease  | • Antipseudomonal agents                                    | • Fluoroquinolone with enhanced pneumococcal activity plus benzylpenicillin | • β-Lactam + macrolide                                    |
| Suspected aspiration     | • Fluoroquinolone ± clindamycin                             |                                                  |                                                            |
|                          | • Metronidazole                                             |                                                  |                                                            |
|                          | • β-Lactam/β-lactamase inhibitor                            |                                                  |                                                            |

with “severe” CAP (SCAP). Therefore, a reliable prognostic model might be useful in tailoring empirical therapy in individual patients. Pragmatically, SCAP could be defined by the need of ICU admission. However, this definition does not include objective measurements and depends on local policies for ICU admission that may vary considerably between centers. The ATS proposed to define SCAP on the presence of a certain set of minor and major clinical signs or symptoms. The British Thoracic Society defined SCAP using a more or less similar set of “core,” “additional,” and “preexisting” adverse prognostic features. Another algorithm to predict mortality risk and thus severity of CAP is the Pneumonia...
Severity Index (PSI), which classifies patients in five groups. In the development of this scoring system, 30-day mortality rates gradually increased per class from 0.1% in class I, to 31.1% in class V. The ATS criteria had a high sensitivity but low specificity for predicting ICU admission and in another study only 17% of patients in risk class V of the PSI system had been admitted to ICU. To what extent these criteria and algorithms can be used for choosing empirical therapy remains to be determined. In our view, clinical judgment, which is difficult to describe in objective terms, remains important in the management of patients with CAP.

Results of nonexperimental studies have suggested that, in the initial management of patients hospitalized with CAP who do not require ICU admission, combination therapy consisting of a β-lactam antibiotic plus a macrolide or monotherapy with one of the newer fluoroquinolones reduces mortality and length of hospitalization. Naturally, such strategies would increase the use of macrolides and fluoroquinolones and thus the selective antibiotic pressure for resistance. The beneficial value of macrolides or fluoroquinolones might be the result of a larger than previously assumed role of atypical pathogens in the etiology of CAP, anti-inflammatory effects of macrolides, or resistance to β-lactams of the most important pathogens. However, the nonexperimental, and in almost all cases retrospective, design of these studies may have resulted in confounding by indication. Up till now, randomized controlled trials do not confirm these outcome differences.

The newer fluoroquinolones (levofloxacin and moxifloxacin) have been compared to β-lactam antibiotics (co-amoxiclav and ceftriaxone) with or without a macrolide in three randomized trials. Clinical and bacteriological success of fluoroquinolone treatment appeared to be better in two studies and statistically significant differences in fever resolution and duration of hospitalization, in favor of fluoroquinolone treated patients, were also observed in two studies. Yet, the absolute differences were rather small (about 1 day for fever resolution and hospitalization), a significant survival benefit was not found, and results might have been influenced by protocol in at least one study, in which a switch to oral treatment for patients receiving ceftriaxone was not allowed before day 7.

In adults with nonsevere CAP, treatment failures were comparable for empirical regimens with atypical coverage as compared to β-lactam antibiotics in meta-analysis. A similar conclusion of was reached in another meta-analysis of 24 trials, evaluating more than 5000 patients, treated for CAP. A trend toward increased clinical success and better bacteriological eradication was found for patients receiving atypical coverage, especially for those infected with Legionella pneumophila. Yet, this trend disappeared when only high-quality studies were evaluated. Therefore, the recommendation to use empirical treatment with either a β-lactam/macrolide combination or monotherapy with a new fluoroquinolone for patients hospitalized with CAP is based on studies providing, at most, level III evidence.
Length of Treatment

The recommended length of antimicrobial treatment of CAP is usually based on the causative pathogen, response to treatment, presence of comorbid illness, and complications. Current guidelines recommend to treat CAP caused by *S. pneumoniae* until the patient has been afebrile for 72 hours, whereas episodes caused by bacteria associated with pulmonary necrosis (e.g., *S. aureus*, *P. aeruginosa*, *Klebsiella*, and anaerobes) should be treated for about 2 weeks.\(^5^1\) A duration of 2 weeks is also recommended for CAP caused by *M. pneumoniae*, *C. pneumoniae*, and legionnaires’ disease in immunocompetent individuals. Treatment length could be reduced by using azithromycin, due to its long half-life in tissues, although longer courses are probably needed for *Legionella* infections.\(^5^1, 8^6\)

These recommendations on treatment duration are not based on results of controlled trials. Recently, treatment durations of 3 and 8 days with amoxicillin ± clavulanic acid were compared in a randomized double-blind trial of 186 adult patients with mild CAP. At day 10, outcomes for clinical success, pathogen eradication, radiological response, and duration of hospitalization were similar for both groups, whereas adverse reactions occurred more frequently among patients receiving 8 days of amoxicillin.\(^8^7\)

In conventional treatment approaches, intravenous therapy is continued until definite clinical cure has been achieved. Based on nonrandomized studies in patients with mild to moderately severe CAP, patients hospitalized with CAP can be managed safely and more efficiently by an early switch from IV to oral medication.\(^8^8–9^3\) For patients with severe CAP, an early switch to oral antibiotic treatment also seems to reduce length of hospital stay (by approximately 2 days) and treatment associated costs, without adverse effects on treatment outcome.\(^9^4\)

Prevention

Prevention of CAP, for instance through vaccination, may well reduce antibiotic use and thus resistance development. With regard to respiratory infections, vaccines are available against pneumococci and influenza. Currently, a 23-valent pneumococcal polysaccharide vaccine (PPV), covering the 23 most prevalent serotypes of *S. pneumoniae*, is recommended in most Western countries for persons at high risk for developing CAP. However, the available data to support these recommendations are far from consistent. Nonexperimental retrospective studies suggest that PPV is effective and cost-saving in preventing invasive pneumococcal disease.\(^9^5, 9^6\) However, confounding by indication might have played a considerable role in these studies affecting the validity of the results. Several clinical studies and systematic reviews yielded conflicting results with regard to the prevention of bacteremic pneumonia even in high-risk patients who were previously hospitalized with CAP.\(^9^6–10^2\) Therefore, the
real value of pneumococcal vaccination strategies, in terms of effects on nonbacteremic pneumonia and costs, needs further exploration, preferably in randomized controlled trials.\textsuperscript{103, 104}

Influenza vaccination is recommended for patients who have a high risk for influenza complications, like severe viral pneumonia or severe secondary bacterial infection. Patients at high risk for these complications can be identified based on host characteristics such as age, gender, comorbidity, and external factors, such as long-term immunosuppressive drug use or residence in closed communities with high transmission rates.\textsuperscript{105} In meta-analysis vaccine effectiveness was 50% for preventing hospitalization and 68% for preventing death in high-risk patients. In addition to elderly patients, younger persons with high-risk medical conditions might also benefit from annual influenza vaccination.\textsuperscript{101, 106, 107} Data on clinical effectiveness of the vaccine in reducing postinfluenza complications among high-risk persons of working age are limited and indicate no or at most limited benefits from vaccination.\textsuperscript{102, 105, 108} Quantitative effects on antibiotic use of influenza vaccination are unknown, but it is tempting to argue that an effective influenza vaccination program might reduce antibiotic use.

Conclusions

CAP is still among the most frequently encountered infections and accounts for considerable antibiotic consumption. Strategies to fight antibiotic resistance on a population level include several basic approaches: only treat when necessary, prescribe antibiotics for bacterial infections only, only treat causative pathogens, and reduce duration of treatment as much as possible. Physicians caring for CAP patients should balance these principles against the optimal treatment of the individual patient, which frequently includes broad-spectrum antibiotics as empirical therapy, especially in patients with severe CAP. As clinical features cannot adequately predict the causative microorganism, establishing an etiological diagnosis by means of urinary antigen tests or real-time PCR techniques may enhance streamlining of therapy, thereby reducing antibiotic pressure. Current guidelines advise broad spectrum antibiotics either with combinations of β-lactam antibiotics plus macrolides or monotherapy with fluoroquinolones for empirical treatment of severe CAP. Yet, different definitions are used for CAP severity and the recommendation of early broad-spectrum therapy is not supported by high-level evidence. The effects of these recommendations on resistance development are not clear, but should be a reason for concern.

More restrictive and prudent, but still responsible, use of antibiotics for CAP could possibly be achieved by improving techniques to establish etiological diagnoses, by optimizing empirical treatment through randomized trials, by optimizing duration of therapy, and implementation of vaccination strategies. However, these hypotheses remain to be proven.
References

1. Marrie TJ. Community-acquired pneumonia. Clin Infect Dis 1994;18:501–513.
2. Chow AW, Hall CB, Klein JO, et al. General guidelines for the evaluation of new anti-infective drugs for the treatment of respiratory tract infections. Clin Infect Dis 1992;15:s62–s88.
3. Koivula I, Sten M, Makela PH. Risk factors for pneumonia in the elderly. Am J Med 1994;96:313–320.
4. Lipsky BA, Boyko EJ, Inui TS, Koepsell TD. Risk factors for acquiring pneumococcal infections. Arch Intern Med 1986;146:2179–2185.
5. Roson B, Carratala J, Fernandez-Sabe N, et al. Causes and factors associated with early failure in hospitalized patients with community-acquired pneumonia. Arch Intern Med 2004;164:502–508.
6. Moine P, Vercken JB, Chevret S, Chastang C, Gajdos P. Severe community-acquired pneumonia. Etiology, epidemiology, and prognosis factors. French Study Group for Community-Acquired Pneumonia in the Intensive Care Unit. Chest 1994;105:1487–1495.
7. Torres A, Serra-Batilles J, Ferrer A, et al. Severe community-acquired pneumonia. Epidemiology and prognostic factors. Am Rev Respir Dis 1991;144:312–318.
8. Pinner RW, Teutsch SM, Simonsen L, et al. Trends in infectious diseases mortality in the United States. JAMA 1996;275:189–193.
9. Thompson WW, Shay DK, Weintraub E, et al. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 2003;289:179–186.
10. Pneumonia and influenza death rates—United States, 1979–1994. MMWR 1995;44:535–537.
11. Fry AM, Shay DK, Holman RC, Curns AT, Anderson LJ. Trends in hospitalizations for pneumonia among persons aged 65 years or older in the United States, 1988–2002. JAMA 2005;294:2712–2719.
12. Oosterheert JJ, Bonten MJ, Hak E, et al. [The increase in pneumonia-related morbidity and mortality among adults in the Netherlands and possible explanations for it]. Ned Tijdschr Geneeskd 2004;148:1765–1769.
13. Guest JF, Morris A. Community-acquired pneumonia: The annual cost to the National Health Service in the UK. Eur Respir J 1997;10:1530–1534.
14. Marston BJ, Plouffe JF, File TM Jr, et al. Incidence of community-acquired pneumonia requiring hospitalization. Results of a population-based active surveillance study in Ohio. The Community-Based Pneumonia Incidence Study Group. Arch Intern Med 1997;157:1709–1718.
15. Lave JR, Lin CJ, Fine MJ, Hughes-Cromwick P. The cost of treating patients with community-acquired pneumonia. Semin Respir Crit Care Med 1999;20:189–197.
16. Ball P, Baquero F, Cars O, et al. Antibiotic therapy of community respiratory tract infections: Strategies for optimal outcomes and minimized resistance emergence. J Antimicrob Chemother 2002;49:31–40.
17. Ruiz M, Ewig S, Marcos MA, et al. Etiology of community acquired pneumonia: Impact of age, comorbidity and severity. Am J Respir Crit Care Med 1999;160:397–405.
18. Lim WS, Macfarlane JT, Boswell TCJ, et al. Study of community acquired pneumonia aetiology (SCAPA) in adults admitted to hospital: Implications for management guidelines. Thorax 2001;56:296–301.
19. Park DR, Sherbin VL, Goodman MS, et al. The etiology of community-acquired pneumonia at an urban public hospital: Influence of human immunodeficiency virus infection and initial severity of illness. J Infect Dis 2001;184:268–277.

20. Lieberman D, Schlaeffer F, Boldur I, et al. Multiple pathogens in adult patients admitted with community-acquired pneumonia: A one year prospective study of 346 consecutive patients. Thorax 1996;51:179–184.

21. Luna CM, Famiglietti A, Absi R, et al. Community-acquired pneumonia: Etiology, epidemiology, and outcome at a teaching hospital in Argentina. Chest 2000;118:1344–1354.

22. Finch R, Schurmann D, Collins O, et al. Randomized controlled trial of sequential intravenous (i.v.) and oral moxifloxacin compared with sequential i.v. and oral co-amoxiclav with or without clarithromycin in patients with community-acquired pneumonia requiring initial parenteral treatment. Antimicrob Agents Chemother 2002;46:1746–1754.

23. Bohte R, Furth R van, Broek PJ van den. Aetiology of community-acquired pneumonia; a prospective study among adults requiring admission to hospital. Thorax 1995;50:543–547.

24. Vegelin AL, Bissumbhar P, Joore JCA, Lammers JWJ, Hoepelman IM. Guidelines for severe community-acquired pneumonia in the western world. Neth J Med 1999;55:110–117.

25. van Elden LJ, van Loon AM, van Alphen F, et al. Frequent detection of human coronaviruses in clinical specimens from patients with respiratory tract infection by use of a novel real-time reverse-transcriptase polymerase chain reaction. J Infect Dis 2004;189:652–657.

26. Falsey AR, Walsh EE, Hayden FG. Rhinovirus and coronavirus infection-associated hospitalizations among older adults. J Infect Dis 2002;185:1338–1341.

27. Drosten C, Gunther S, Preiser W, et al. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N Engl J Med 2003;348:1967–1976.

28. Ksiazek TG, Erdman D, Goldsmith CS, et al. A novel coronavirus associated with severe acute respiratory syndrome. N Engl J Med 2003;348:1953–1966.

29. Woo PC, Lau SK, Tsoi HW, et al. Relative rates of non-pneumonic SARS coronavirus infection and SARS coronavirus pneumonia. Lancet 2004;363:841–845.

30. Vabret A, Mourez T, Gouarin S, Petitjean J, Freymuth F. An outbreak of coronavirus OC43 respiratory infection in Normandy, France. Clin Infect Dis 2003;36:985–989.

31. Hoek vdL, Pyrc K, Jebbink MF, et al. Identification of a new human coronavirus. Nat Med 2004;10:368–373.

32. Kahn JS. Human metapneumovirus: A newly emerging respiratory pathogen. Curr Opin Infect Dis 2003;16:255–258.

33. van den Hoogen BG, de Jong JC, Groen J, et al. A newly discovered human pneumovirus isolated from young children with respiratory tract disease. Nat Med 2001;7:719–724.

34. Farr BM, Kaiser DL, Harrison BDW, Connolly CK. Prediction of microbial aetiology at admission to hospital for pneumonia from the presenting clinical features. Thorax 1989;44:1031–1035.

35. Macfarlane JT, Miller AC, Roderick Smith WH, Morris AH, Rose DH. Comparative radiographic features of community-acquired legionnaires’ disease, pneumococcal pneumonia, mycoplasma pneumonia and psittacosis. Thorax 1984;39:28–33.
36. Woodhead MA, Macfarlane JT, American Thoracic Society. Comparative clinical and laboratory features of legionella with pneumococcal and mycoplasma pneumonias. Br J Dis Chest 1987;81:133–139.
37. Bohte R, Hermans J, van den Broek PJ. Early recognition of Streptococcus pneumoniae in patients with community-acquired pneumonia. Eur J Clin Microbiol Infect Dis 1996;15:201–205.
38. Hopstaken RM, Muris JW, Knottnerus JA, et al. Contributions of symptoms, signs, erythrocyte sedimentation rate, and C-reactive protein to a diagnosis of pneumonia in acute lower respiratory tract infection. Br J Gen Pract 2003;53:358–364.
39. Hopstaken RM, Stobberingh EE, Knottnerus JA, et al. Clinical items not helpful in differentiating viral from bacterial lower respiratory tract infections in general practice. J Clin Epidemiol 2005;58:175–183.
40. Michelow IC, Olsen K, Lozano J, et al. Epidemiology and clinical characteristics of community-acquired pneumonia in hospitalized children. Pediatrics 2004;113:701–707.
41. Toikka P, Irjala K, Juven T, et al. Serum procalcitonin, C-reactive protein and interleukin-6 for distinguishing bacterial and viral pneumonia in children. Pediatr Infect Dis J 2000;19:598–602.
42. Christ-Crain M, Jaccard-Stolz D, Bingisser R, et al. Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections: Cluster-randomised, single-blinded intervention trial. Lancet 2004;363:600–607.
43. Waterer GW, Jennings SG, Wunderink RG. The impact of blood cultures on antibiotic therapy in pneumococcal pneumonia. Chest 1999;116:1278–1281.
44. Ewig S, Schlochtermeier M, Goke N, Niederman MS. Applying sputum as a diagnostic tool in pneumonia: Limited yield, minimal impact on treatment decisions. Chest 2002;121:1486–1492.
45. Reed WW, Byrd GS, Gates RH Jr, et al. Sputum Gram’s stain in community acquired pneumonia: A meta analysis. West J Med 1996;165:197.
46. Smith PR. What diagnostic tests are needed for community-acquired pneumonia. Med Clin North Am 2001;85:1381–1396.
47. Corbo J, Friedman B, Bijur P, Gallagher EJ. Limited usefulness of initial blood cultures in community acquired pneumonia. Emerg Med J 2004;21:446–448.
48. van der Eerden MM, Vlaspolder F, de Graaff CS, et al. Value of intensive diagnostic microbiological investigation in low- and high-risk patients with community-acquired pneumonia. Eur J Clin Microbiol Infect Dis 2005;24:241–249.
49. van der Eerden MM, Vlaspolder F, de Graaff CS, et al. Comparison between pathogen directed antibiotic treatment and empirical broad spectrum antibiotic treatment in patients with community acquired pneumonia: A prospective randomised study. Thorax 2005;60:672–678.
50. American Thoracic Society. Guidelines for the management of adults with community acquired pneumonia. Am J Crit Care Med 2001;163:1730–1754.
51. Bartlett JG, Dowell SF, Mandell LA, et al. Practice guidelines for the management of community-acquired pneumonia in adults. Infectious Diseases Society of America. Clin Infect Dis 2000;31:347–382.
52. Skov Sorensen UB, Henrichsen J. Cross-reactions between pneumococci and other streptococci due to C polysaccaride and F antigen. J Clin Microbiol 1987;25:1854–1859.
53. Murdoch DR, Laing RT, Mills GD, et al. Evaluation of a rapid immunochromato-
graphic test for detection of Streptococcus pneumoniae antigen in urine samples from
adults with community-acquired pneumonia. Clin Microbiol 2001;39:3495–3498.
54. Dowell SF, Garman RL, Liu G, Levine OS, Yang YH. Evaluation of Binax NOW, an
assay for the detection of pneumococcal antigen in urine samples, performed among
pediatric patients. Clin Infect Dis 2001;32:824–825.
55. Yzerman EP, den Boer JW, Lettinga KD, et al. Sensitivity of three urinary antigen
tests associated with clinical severity in a large outbreak of Legionnaires’ disease in
the Netherlands. Clin Microbiol 2002;40:3232–3236.
56. Lettinga KD, Verbon A, Weverling GJ, et al. Legionnaires’ disease at a Dutch flower
show: Prognostic factors and impact of therapy. Emerg Infect Dis 2002;8:1448–1454.
57. Elden LJ van, Nijhuis M, Schipper P, Schuurman R, Loon AM van. Simultaneous
detection of influenza viruses A and B using real-time quantitative PCR. Clin
Microbiol 2001;39:196–200.
58. Oosterheert JJ, van Loon AM, Schuurman R, et al. Impact of rapid detection of viral
and atypical bacterial pathogens by real-time polymerase chain reaction for patients
with lower respiratory tract infection. Clin Infect Dis 2005;41:1438–1444.
59. Craig WA. Pharmacokinetic/pharmacodynamic parameters: Rationale for antibacterial
dosing of mice and men. Clin Infect Dis 1998;26:1–10.
60. Garau J. Treatment of drug-resistant pneumococcal pneumonia. Lancet Infect Dis
2002;2:404–415.
61. Davidson R, Cavalcanti R, Brunton J, et al. Resistance to levofloxacin and failure of
treatment of pneumococcal pneumonia. N Engl J Med 2002;346:747–749.
62. Low DE. Quinolone resistance among pneumococci: Therapeutic and diagnostic
implications. Clin Infect Dis 2004;38 Suppl 4:S357-S362.
63. Johnston NJ, De Azavedo JC, Kellner JD, Low DE. Prevalence and characterization
of the mechanisms of macrolide, lincosamide, and streptogramin resistance in isolates
of Streptococcus pneumoniae. Antimicrob Agents Chemother 1998;42:2425–2426.
64. Miller LG, Perdreau-Remington F, Rieg G, et al. Necrotizing fasciitis caused by com-
nunity-associated methicillin-resistant Staphylococcus aureus in Los Angeles.
N Engl J Med 2005;352:1445–1453.
65. Bradley SF. Staphylococcus aureus pneumonia: Emergence of MRSA in the commu-
nity. Semin Respir Crit Care Med 2005;26:643–649.
66. Neuhaus T, Ewig S. Defining severe community-acquired pneumonia. Med Clin
North Am 2001;85:1413–1425.
67. BTS Guidelines for the Management of Community Acquired Pneumonia in Adults.
Thorax 2001;56 Suppl 4:IV1–64.
68. Ewig S, Ruiz M, Mensa J, et al. Severe community-acquired pneumonia. Assessment
of severity criteria. Am J Respir Crit Care Med 1998;158:1102–1108.
69. Fine MJ, Auble TE, Yealy DM, et al. A prediction rule to identify low-risk patients
with community acquired pneumonia. N Engl J Med 1997;336:243–250.
70. Lim WS, van der Eerden MM, Laing R, et al. Defining community acquired pneu-
monia severity on presentation to hospital: An international derivation and validation
study. Thorax 2003;58:377–382.
71. Martinez JA, Horcajada JP, Almela M, et al. Addition of a macrolide to a beta-
lactam-based empirical antibiotic regimen is associated with lower in-hospital mor-
tality for patients with bacteremic pneumococcal pneumonia. Clin Infect Dis
2003;36:389–395.
72. Burgess DS, Lewis JS. Effect of macrolides as part of initial empiric therapy on medical outcomes for hospitalized patients with community-acquired pneumonia. Clin Ther 2000;22:872–878.

73. Dudas V, Hopefl A, Jacobs R, Guglielmo BJ. Antimicrobial selection for hospitalized patients with presumed community-acquired pneumonia: A survey of nonteaching US community hospitals. Ann Pharmacother 2000;34:446–452.

74. Gleason PP, Meehan TP, Fine JM, Galusha DH, Fine MJ. Associations between initial antimicrobial therapy and medical outcomes for hospitalized elderly patients with pneumonia. Arch Intern Med 1999;159:2562–2572.

75. Houck PM, MacLehose RF, Niederman MS, Lowery JK. Empiric antibiotic therapy and mortality among Medicare pneumonia inpatients in 10 western states. Chest 2001;119:1420–1426.

76. Mufson MA, Stanek RJ. Bacteremic pneumococcal pneumonia in one American city: A 20-year longitudinal study, 1978–1997. Am J Med 1999;107:34S-43S.

77. Stahle JE, Barza M, DesJardin J, Martin R, Eckman MH. Effect of macrolides as part of initial empiric therapy on length of stay in patients hospitalized with community-acquired pneumonia. Arch Intern Med 1999;159:2576–2580.

78. Waterer GW, Somes GW, Wunderink RG. Monotherapy may be suboptimal for severe pneumococcal pneumonia. Arch Intern Med 2001;161:1837–1842.

79. Neuhauser MM, Weinstein RA, Rydman R, et al. Antibiotic resistance among gram-negative bacilli in US intensive care units: Implications for fluoroquinolone use. JAMA 2003;289:885–888.

80. McCormick AW, Whitney CG, Farley MM, et al. Geographic diversity and temporal trends of antimicrobial resistance in Streptococcus pneumoniae in the United States. Nat Med 2003;9:424–430.

81. Oosterheert JJ, Bonten MJ, Schneider MM, Hoepelman IM. Predicted effects on antibiotic use following the introduction of British or North American guidelines for community-acquired pneumonia in the Netherlands. Clin Microbiol Infect 2005;11:992–998.

82. File TM Jr, Segreti J, Dunbar L, et al. A multicenter, randomized study comparing the efficacy and safety of intravenous and/or oral levofloxacin versus ceftiraxone and/or cefuroxime axetil in treatment of adults with community-acquired pneumonia. Antimicrob Agents Chemother 1997;41:1965–1972.

83. Welte T, Petermann W, Schurmann D, Bauer TT, Reimnitz P. Treatment with sequential intravenous or oral moxifloxacin was associated with faster clinical improvement than was standard therapy for hospitalized patients with community-acquired pneumonia who received initial parenteral therapy. Clin Infect Dis 2005;41:1697–1705.

84. Mills GD, Oehley MR, Arrol B. Effectiveness of beta lactam antibiotics compared with antibiotics active against atypical pathogens in non-severe community acquired pneumonia: meta-analysis. BMJ 2005;330:456.

85. Shefet D, Robenshtok E, Paul M, Leibovici L. Empirical atypical coverage for inpatients with community-acquired pneumonia: Systematic review of randomized controlled trials. Arch Intern Med 2005;165:1992–2000.

86. Matute AJ, Schurink CA, Hoepelman IM. Is a 5 day course of azithromycin enough for infections caused by Legionella pneumophila? J Antimicrob Chemother 2000;45:930–931.

87. El Moussaoui R., Prins J, et al. Three versus eight days of amoxicillin in mild to moderate-severe CAP. Program and Abstracts of the 44th Interscience Conference of Antimicrobial Agents and Chemotherapy 2004, Abstract L-661. Washington, DC.
88. Rhew DC, Weingarten SR. Achieving a safe and early discharge for patients with community-acquired pneumonia. Med Clin North Am 2001;85:1427–1440.
89. Ramirez JA, Srinath L, Ahkee S, Huang A, Raff MJ. Early switch from intravenous to oral cephalosporins in the treatment of hospitalized patients with community-acquired pneumonia. Arch Intern Med 1995;155:1273–1276.
90. Ramirez JA, Vargas S, Ritter GW, et al. Early switch from intravenous to oral antibiotics and early hospital discharge: A prospective observational study of 200 consecutive patients with community-acquired pneumonia. Arch Intern Med 1999;159:2449–2454.
91. Siegel RE, Halpern NA, Almenoff PL, et al. A prospective randomized study of inpatient iv. antibiotics for community-acquired pneumonia. The optimal duration of therapy. Chest 1996;110:965–971.
92. Siegel RE, Halpern NA, Almenoff PL, et al. A prospective randomized study of inpatient iv. antibiotics for community-acquired pneumonia. The optimal duration of therapy. Chest 1996;110:965–971.
93. Castro-Guardiola A, Viejo-Rodriguez AL, Soler-Simon S, et al. Efficacy and safety of oral and early-switch therapy for community-acquired pneumonia: A randomized controlled trial. Am J Med 2001;111:367–374.
94. Oosterheert JJ, Bonten MJ, Schneder MM, et al. Effectiveness of early switch from intravenous to oral antibiotics in severe community acquired pneumonia: multicentre randomised trial. BMJ. 2006 Dec 9;333(7580):1193
95. Sisk JE, Moskowitz AJ, Whang W, et al. Cost-effectiveness of vaccination against pneumococcal bacteremia among elderly people. JAMA 1997;278:1333–1339.
96. Ortvqvist A, Hedlund J, Burman LA, et al. Randomised trial of 23-valent pneumococcal capsular polysaccharide vaccine in prevention of pneumonia in middle-aged and elderly people. Swedish Pneumococcal Vaccination Study Group. Lancet 1998;351:399–403.
97. Appelbaum PC. Resistance among Streptococcus pneumoniae: Implications for drug selection. Clin Infect Dis 2002;34:1613–1620.
98. Gross PA. Vaccines for pneumonia and new antiviral therapies. Med Clin North Am 2001;85:1531–1544.
99. Hak E, Grobbee DE, van Essen GA, Buskens E, Verheij TJ. Pneumococcal vaccination of the elderly: Do we need another trial? Arch Intern Med 2000;160:1698–1699.
100. Nichol KL, Baken L, Wuorenma J, Nelson A. The health and economic benefits associated with pneumococcal vaccination of elderly persons with chronic lung disease. Arch Intern Med 1999;159:2437–2442.
101. Christenson B, Lundbergh P, Hedlund J, Ortvqvist A. Effects of a large-scale intervention with influenza and 23-valent pneumococcal vaccines in adults aged 65 years or older: A prospective study. Lancet 2001;357:1008–1011.
102. Ahmed F, Singleton JA, Franks AL. Clinical practice. Influenza vaccination for healthy young adults. N Engl J Med 2001;345:1543–1547.
103. Ament A, Fedson DS, Christie P. Pneumococcal vaccination and pneumonia: Even a low level of clinical effectiveness is highly cost-effective. Clin Infect Dis 2001;33:2079.
104. Ament A, Baltussen R, Duru G, et al. Cost-effectiveness of pneumococcal vaccination of older people: A study in 5 western European countries. Clin Infect Dis 2001;31:444–450.
105. Hak E, Hoes A, Verheij TJ. Influenza vaccination. Who needs them and when? Drugs 2002;62:2413–2420.
106. Hak E, Buskens E, van Essen GA, et al. Clinical effectiveness of influenza vaccination in persons younger than 65 years with high-risk medical conditions: The PRISMA study. Arch Intern Med 2005;165:274–280.

107. Gross PA, Hermogenes AW, Sacks HS, Lau J, Levandowski RA. The efficacy of influenza vaccine in elderly persons. A meta-analysis and review of the literature. Ann Intern Med 1995;123:518–527.

108. Demicheli V, Jefferson T, Rivetti D, Deeks J. Prevention and early treatment of influenza in healthy adults. Vaccine 2000;18:957–1030.